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ABSTRACT 
Introduction: Nowadays follicular lymphoma (FL) is considered a virtually incurable disease. 
Nevertheless, an improvement of prognostic criteria must be pursued in order to achieve new 
treatment strategies based on a personalized approach.  
Areas covered: Prognostic scores, old and recent, as well as innovative and experimental 
therapeutic approaches are constantly evaluated when it comes to discussing the proper approach to 
FL, due to its extremely variable presentation at diagnosis. For asymptomatic, low-tumor burden 
FL, a “watch & wait” policy is currently the first-choice approach, although possible alternatives 
are discussed. Early stage FL may be treated with local radiotherapy although the role of minimal 
residual disease in possible additional agents should be determined. The first line treatment for 
symptomatic FL is chemo-immunotherapy followed by two years maintenance therapy with anti-
CD20 monoclonal antibodies. A deeper knowledge of FL biology has opened new perspectives 
regarding the timing of therapy and has offered new targets for the development of novel agents that 
aim to change the therapeutic scenario of FL management.  
Expert commentary: The introduction of novel agents could question the incurability of FL and 
change the therapeutic goal from prolonging the complete remission state to eradicating the disease 
in young/fit patients, as well as improving quality of life in elderly/unfit patients. In the near future, 
combining new biologic agents and adoptive cell therapies could help in achieving these aims. 
Keywords: follicular lymphoma, molecular biology, MRD, novel agents, PET, prognosis, stem-cell 
transplant 
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1. Background 
Follicular lymphoma (FL) is the second most frequent subtype of nodal lymphoid malignancy in 
Western Europe affecting roughly 5/100.000 individuals per year1. The genetic hallmark of FL is 
the translocation t(14;18)(q32;q21) leading to overexpression of the anti-apoptotic B-cell 
lymphoma/leukemia 2 (BCL2) oncogene2. However, up to 50% of FL cases lack the t(14;18) 
translocation depending on disease stage3. The detailed mechanisms of FL ontogenesis were 
recently better clarified, opening the possibility to new therapeutic approaches2. Besides t(14;18) 
translocation, recurrent gene aberrations such as TNFRSF14, EPHA7, EZH2, CREBBP, EP300, 
MLL2 and MEF2B have been identified4. A few t(14;18)-positive B cells can be detected in healthy 
subjects, and these B cells are reported to have their own biological features that are closely related 
to the pathogenesis of FL5. On the other hand, FL is characterized by a unique microenvironment, 
which allows the survival and development of FL subclones6. Diagnosis is based on the peculiar 
histologic nodular pattern, in which the relationship of centrocytes and centroblasts defines different 
grades from 1 to 3, the latter classification divided into 3A and 3B grades: 3B is almost completely 
composed of centroblasts with a nodular growth pattern and is considered similar to a diffuse large 
B cell lymphoma (WHO)7. The initial work-up for staging includes bone marrow biopsy and 
computed tomography (CT). Positron emission tomography (PET)-CT is used for pre-treatment 
tumor burden assessment, improving the accuracy of staging, as well as to evaluate the response to 
treatment. Also, its role in the identification of truly localized cases (Ann Arbor stage I/II) is 
essential8. Several prognostic algorithms were developed: “follicular lymphoma international 
prognostic index- FLIPI” created before rituximab introduction; post-rituximab era (FLIPI2) and 
more recently with the support of molecular biology m7-FLIPI9,10,11. Using micro-array profiling, 
Huet et al built a 23-gene expression-based predictor of progression free survival (PFS), able to 
identify those patients with a high risk of early progression12. These scores, although efficiently 
separating patients in different risk groups, are not currently used to choose different treatment 
strategies. The therapeutic approach still mainly depends on symptoms and stage. Around 10-20% 
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of FL according to WHO occur with a limited stage (Ann Arbor stages I and II)13 at diagnosis. 
These cases are mainly approached with involved-field radiotherapy (IF-RT)14. The role of R 
consolidation is under evaluation (see below). The advanced stages (Ann Arbor stages III and IV) 
are further divided in to asymptomatic-low-tumor burden patients and treatment requiring patients, 
as defined by the GELF criteria (table 4)15. These two entities have a different therapeutic strategy: 
for low-tumor burden, treatment is usually deferred due to the indolent course of the disease, until 
symptom occurrence or disease progression. For advanced stage symptomatic FL, an early 
treatment with combined regimens of chemo-immunotherapy is recommended16,17. The present 
paper aims to review the current literature on present and future therapeutic approaches for the 
treatment of FL. 
 
1.1 Molecular detection of BCL2/IGH rearrangement 
The t(14;18) translocation (q32;q21) causes the juxtaposition of the BCL2 oncogene to the 
immunoglobulin heavy chain gene (IGH), resulting in an over-expression of the BCL2 protein and, 
consequently, in the clonal deregulation of cell cycle control and apoptosis18,19. This event is 
considered the first hit of a multistep process leading to the acquisition of a number of additional 
genetic or epigenetic events leading to FL development and/or progression20. The t(14;18) can be 
molecularly investigated in the peripheral blood (PB) and/or bone marrow (BM), providing a 
sensitive tool for minimal residual disease (MRD) detection after treatment and in the follow-up 
with prognostic implications. The European group BIOMED has developed polymerase chain 
reaction (PCR)-based protocols for the identification of the BCL2/IGH rearrangement21. The 
available markers are: MBR (major breakpoint region), mcr (minor cluster region)22 and 
3’MBR/5’mcr (minor BCL2 rearrangements)23. The real time TaqMan PCR approach (RQ-PCR) is 
used for the quantification of the MBR rearrangements, while no validated assay is yet available for 
the study of the other breakpoints. The third generation droplet digital PCR (ddPCR), has recently 
been tested in a few studies (including one from our team24) showing a comparable sensitivity and a 
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potentially greater accuracy for the detection and quantification of molecular targets25. The 
predictive role of MRD has already been established in advanced stage FL, by a large FIL 
(Federazione Italiana Linfomi) trial (FOLL05) which confirmed that MRD negativity after 
treatment was predictive of a better PFS compared to MRD positivity26. As regards early stage FL, 
in a previous work we showed that despite a negative bone marrow biopsy, tumour cells can 
contaminate the PB and/or BM in about 60% of patients at diagnosis27. This is relevant for 
lymphoma physiopathology and the definition of the disease extension at presentation28. Moreover, 
we reported that IF-RT on the primary site of the disease was able to clear BCL2/IGH+ cells from 
the PB and BM in more than 50% of the cases, when the basal level of circulating lymphoma cells 
was <1x10-5 27. These findings have brought to the ongoing FIL trials (FOLL12 -EudraCT: 2012-
003170-60- for advanced stage and MIRO’ -EudraCT: 2012-001676-11- for early stage FL, 
respectively), in which MRD drives the post-induction treatment with anti-CD20 monoclonal 
antibodies (moAbs).  
 
1.2 FDG-PET in FL 
The role of F-fluorodeoxyglucose (FDG)-PET in diagnosis and staging of FL has been extensively 
studied and, since 2014, after the publication of the so called “Lugano Classification”, it has entered 
the routine clinical practice29,30. In the field of indolent lymphomas, FL has a high avidity for FDG 
and, for this reason, PET has shown high rates of sensitivity and specificity when compared to CT 
alone30. Advantages are evident in defining both nodal and extranodal disease localizations, offering 
a reliable method for staging patients with FL31. In particular, as demonstrated by Luminari et al., 
the impact of PET on staging was higher for patients with early stage disease: in a population of 142 
patients from the FOLL05 trial, 62% initially defined as stage II were actually upgraded to stage III 
or IV, with relevant prognostic and therapeutic implications32. However, PET has sub-optimal 
specificity and sensitivity in defining Bone Marrow Involvement (BMI) (20.3-28.9% sensitivity)33. 
As defined in the study of Perry et al., quantitative evaluation of SUV (Standardized Uptake Value) 
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seems to correlate with BMI: in particular, a SUV <1.7 would exclude the BMI, on the contrary a 
SUV> 2.7 would confirm the BMI34. Despite these results, at present PET cannot replace Bone 
Marrow Biopsy (BMB) in defining BMI32,35,36. Another possible use of PET is to identify active 
disease, in the aim of selecting suitable lymph nodes to be biopsied, as well as areas of histologic 
transformation into aggressive disease. Recently, the focus has shifted to TMTV (Total Metabolic 
Tumor Volume), a functional parameter derived from PET at baseline, which has already shown a 
close correlation with the outcome in terms of PFS and overall survival (OS) in patients with high-
tumor burden FL35. The role of TMTV as an independent prognostic factor in FL has recently been 
demonstrated by Meignan et al: by defining a TMTV cut-off of 510m3, they observed as patients 
with TMTV ≤510m3, compared to those with TMTV> 510m3 had a better prognosis in terms of 5y-
PFS and OS35. In the same study, the combination of TMTV and FLIPI-2 allowed to divide patients 
into three different groups in terms of prognosis. In conclusion, TMTV was defined to be a strong 
predictor of outcome and can be helpful in identifying patients with severe prognosis since 
diagnosis. The utility of PET in the evaluation of response after induction chemotherapy has been 
demonstrated by three retrospective studies: the LYSA PRIMA trial36, FIL FOLL05 trial37 and 
GOELAM trial38. These studies have highlighted that patients with negative PET after induction 
chemo-immunotherapy present higher rates of PFS and OS than patients with positive PET, as 
shown in Table 1-3. Post-induction PET evaluation is therefore strongly recommended in clinical 
practice.  
 
2. Therapeutic approaches 
2.1 Early stage FL  
A minor part of FL (10 to 20 % according to WHO) are diagnosed as early stage according to the 
Ann-Arbor staging system (stage I-II)8. The correct definition of this particular entity is now more 
accurate with the use of PET/CT, which allows the identification of really localized disease35. Thus, 
this approach is especially recommended for localized FL staging. As regards the treatment of this 
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rare entity, despite the paucity of randomized clinical trials, radiation therapy (RT) is usually 
preferred, resulting in 10-year overall survival (OS) rates of 60–80%, with a median survival of 
approximately 19 years39. Alternatively, an initial observation strategy is also broadly employed 
with some authors reporting similar survival results40. Nevertheless, a recent analysis from the 
SEER registry, has demonstrated a clear OS advantage in patients with early stage FL treated with 
RT vs observation41. Despite the impact of R treatment on the outcome of advanced stage FL, as 
well as many other B-cell lymphomas, is established42-44, its role in early stage FL is less clear, due 
to the rarity of the disease and its very indolent nature45,46. The current European Society of Medical 
Oncology (ESMO), as well as the National Comprehensive Cancer Network (NCCN) guidelines, 
suggest IF-RT as the preferred upfront treatment option in patients with early stage FL, reserving 
watchful waiting (or eventually R as single agent) only to selected cases47. Moreover, RT could 
induce systemic anti-tumor immune response and tumor regression also in sites distant from the 
irradiated ones, note as abscopal effect48. At present, the standard dose for IF-RT is 24 Gy which 
has been demonstrated in a randomized trial to be as effective as higher dosages49. However, these 
guidelines are still not universally followed, since many patients are not treated with IF-RT46.  
The addiction of R to IF-RT in stage I–II FL patients should be hypothesized in the aim of 
controlling distant subclinical disease outside the radiation fields and reducing the systemic relapse 
rate, without the toxicity reported with combined RT and chemotherapy50,51. The MIR 
(Mabthera® and Involved Field Radiation) study, prospective multicenter trial investigated this 
combination, demonstrating a safe toxicity profile and promising results.  
We previously reported on the use of R consolidation in early stage patients with a positive MRD52. 
The results seem to be encouraging in improving PFS, but need to be confirmed in prospective 
trials.  
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2.2 Low-tumor burden FL 
Some patients with advanced stage FL (stage III-IV) are asymptomatic at diagnosis, not fulfilling 
the GELF criteria for the definition of treatment requiring disease (table 4). In this setting, no 
benefit of immediate treatment was recorded when compared with a watchful-waiting approach60. 
Delaying chemotherapy is important in order to avoid side effects, considering disease course. In 
the pre-rituximab era, no difference in OS and cause-specific survival (CSS) was found between the 
group of patients treated with chlorambucil and the observation group. In this last group, the median 
time to systemic treatment was 30 months and 19% of these patients did not require chemotherapy 
at 10 years follow-up (40% if older than 70 years)61. With the advent of anti-CD20 moAbs and their 
low toxicity profile, several trials have investigated the efficacy of R monotherapy in patients with 
low-tumor burden FL (LTBFL). In 2001, P. Colombat et al published the results of a clinical and 
molecular study performed on 50 patients who received R induction (375mg/m2 weekly for 4 
weeks)62. The authors reported an overall response rate (ORR) of 73%, with 20% complete 
response (CR) and 6% unconfirmed CR (CRu). This study showed that R has a high clinical activity 
and a low toxicity inducing a complete molecular remission in this subgroup of patients. In 2012, an 
updated survival analysis of the same cohort was published, with a 7 years follow-up. This analysis 
confirmed the high efficacy of single-agent R: 52% of patients reached CR/CRu63. Moreover, MRD 
was confirmed to be a powerful prognostic tool for PFS. In support of a watchful waiting approach, 
in the F2 study P. Solal-Céligny et al. compared a group of patients with LTBFL who received a R 
based regimen (n=242) to another group of patients who were only observed (n=120)64. The 4-year 
freedom from treatment failure (FFTF) and the OS of the two groups were similar, suggesting that 
observation remains an appropriate approach in asymptomatic patients with LTBFL. In 2014, K. M. 
Ardeshna et al have compared the watchful waiting approach with immediate R treatment in a 
randomized trial involving 379 patients65. The authors concluded that in patients with LTBFL, 
immediate treatment with R monotherapy significantly delays disease progression and time until 
chemotherapy or radiotherapy compared with a watchful waiting approach. Progression-free 
Ac
ce
pte
d M
an
us
cri
pt
survival after maintenance R was significantly better than both watchful waiting and the use of R 
induction without maintenance. Nevertheless, no difference in OS was observed. Overall, R 
monotherapy was well tolerated with a better quality of life (QoL). Basing on these findings, the 
authors suggest R monotherapy for patients with asymptomatic LTBFL. As result, regarding the 
management of patients affected by LTBFL, the generically recommended approach of therapy 
abstention in these asymptomatic patients is surely agreeable, since it does not affect OS and the 
therapy-related toxicity is delayed. Nevertheless, the role of treatment on QoL is questionable: 
many patients show concern in living with cancer without receiving treatment65. Another relevant 
point is the risk of FL transformation to an aggressive lymphoma: there is not a clear-cut answer to 
the question whether the initiation of early treatment is protective against transformation. A huge 
number of patients collected by Federico et al, is currently been analysed retrospectively, attempting 
to demonstrate a possible increased risk of transformation in FL not receiving R in induction and/or 
maintenance. 
2.3 Treatment-requiring FL 
As stated above, patients fulfilling the GELF criteria require an immediate treatment. Currently the 
combination of R plus chemotherapy represents the standard of care for frontline treatment. Four 
prospective studies comparing different poli-chemotherapeutic regimens with or without R have 
shown a significant increase in PFS and OS in R arm67-70. No major adverse events were recorded 
with the addition of R. Whether any of the different chemotherapeutic regimens has clear 
advantages over the alternatives remains currently unanswered. The FOLL05 trial compared R-CVP 
(cyclophosfamide, vincristine, prednisone), R-CHOP (cyclophosfamide, doxorubicin, vincristine, 
prednisone) and R-FM (fludarabine, mitoxantrone), showing that R-CHOP and R-FM resulted in a 
superior PFS compared to R-CVP71. A 2017 update of the same study confirmed this result showing 
that R-CVP was associated with higher risk of lymphoma progression compared to R-CHOP72. 
More recently, another trial from Rummel et al investigated the role of bendamustine (B)-R as an 
alternative first line treatment in this subset of patients. Their results suggested an increase in PFS 
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in the BR arm, compared to R-CHOP (OR:92%, CR: 40% vs OR: 91%, CR: 30% respectively). A 
lower toxicity profile was also recorded73. The results of the BRIGHT study also confirmed the 
non-inferiority of BR compared to R-CHOP and R-CVP, with a better ORR in the BR arm (BR: 
97% vs R-CHOP/R-CVP: 91%) and comparable safety profiles74. BR is currently the standard of 
care for first line treatment of FL in many centers, although some authors still prefer R-CHOP for 
high-risk patients. Grade 3a FL was not included in the analysis of the aforementioned studies; thus, 
there is no formal demonstration of non-inferiority (nor superiority) of BR over R-CHOP in this 
subset of patients. A recent retrospective study analyzed this point suggesting equal or more 
profound efficacy and less toxicity in the BR arm75. Nevertheless, these data need a prospective 
validation. Despite the improvement in ORR and OS brought by R-chemo in these patients, 
progression and/or relapse is a common event. Thus, to increase TTP, several strategies have been 
considered during years: consolidation with radio-immunotherapy or autologous stem cell 
transplantation in first-line did not prove to be useful (see below). Conversely, a maintenance with 
R has proven to be more attractive and gave better results. The PRIMA study, involving 1217 
patients from more than 200 centres, is a randomized comparison of R maintenance vs 
observation76. R maintenance causes an improvement of the results inducing the conversion of more 
than 50% of patients obtaining a partial response (PR) after induction into CR. The update of the 
same analysis confirmed a significant increase in 6-years PFS in the R arm, irrespective of age, 
FLIPI risk, resulting in a higher rate of CR at the end of the 2-year maintenance period. No impact 
on OS was recorded77. Considering the low toxicity profile of R maintenance, the PRIMA trial aims 
to demonstrate a possible role of R maintenance for patients achieving remission after first-line 
treatment. Although an improvement in PFS has been demonstrated after R-CVP, R-CHOP and R-
FCM, a role of R maintenance has still not been proved after BR. However, a sub-analysis of the 
BRIGHT study from the latest ASH-meeting suggested a significant PFS improvement in the BR 
arm treated with R maintenance vs observation78. Whether all subgroups of treatment-requiring FL 
take advantage from R-maintenance is currently being investigated by ongoing studies. More 
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promising in improving the already good results of first line treatment in FL is the introduction of 
other drugs acting with alternative mechanisms to chemotherapy, including novel MoAbs. Several 
trials are exploring these options as illustrated in the dedicated section. One of these, obinutuzumab 
(GA101; G), has currently entered the clinical practice. G is a glycoengineered type II anti-CD20 
mAb which showed a greater direct cell death induction and ADCC/ADCP activity compared to 
R79. It also proved active in association with chemotherapy in patients with NHL who had 
previously received R. Few studies attempted to verify whether a more efficient MoAb could 
improve the already good results obtained by R in combination with chemotherapy. The GALLIUM 
study is a randomized phase III trial which investigated the role of G as a substitute to R both in 
induction (plus chemo) and in maintenance79. At the end of the trial, OS and response rates (CR and 
ORR) were mostly comparable between the two arms, whilst investigator-assessed PFS showed to 
be significantly superior in the experimental arm (G-chemo) compared with the standard one (R-
chemo). Whether G will eventually consolidate as the new standard of care and a potential 
substitute to R is still to be established. Moreover, new chemo-free regimens like Lenalidomide and 
Rituximab and others are under evaluation, as discussed below.  
 
2.4 Relapsed-Refractory FL  
With the introduction of new agents and their combinations, the available options for relapsed-
refractory FL are rapidly increasing. Several trials have investigated the role of novel agents in 
prolonging the outcome of this subset of patients: B monotherapy80, ofatumumab monotherapy81, 
idelalisib monotherapy82. The GADOLIN study was conducted on patients with R-refractory NHL, 
comparing an experimental arm, based on G + B in induction followed by G maintenance with a 
standard arm of single agent B in induction without maintenance83. The updated results of this study 
confirmed that G-B induction plus G maintenance significantly reduces risk of progressive disease 
showing a small advantage also in OS in comparison with B alone 84. This combination is a 
therapeutic option for patient relapsing after R containing first-line treatments. Thus, the choice of 
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several treatment options for relapsed/refractory FL patients, ranging from watch and wait to very 
aggressive approaches, as well as new biologic agents, is influenced by factors such as: age, 
comorbidities, duration of previous CR, amount of previous treatments, current tumor burden and 
biologic features of the disease. In general, in a young and fit FL patient, the aim is a deep and long-
lasting CR and, potentially, the disease eradication. Conversely, in elderly patients and/or with 
comorbidities, the aim could be to obtain a good quality of life with a co-existing disease.  
 
2.5 Role of transplant 
Hematopoietic cell transplantation (HCT), both autologous (auto-) and allogeneic (allo-), has long 
been considered as salvage therapy for relapsed/refractory FL patient . However, the lack of 
randomized trials that compare current treatments with HCT, are questioning the role and the timing 
of transplantation in general and of allo-HCT in particular. Three randomized trials from the pre-
rituximab era85-87 and one from the rituximab era88 evaluated the role of upfront auto-HCT 
consolidation versus observation in patients with advanced stage FL who were in remission after 
first-line therapies. Despite a consistent PFS benefit, suggesting some disease control effect of dose 
intensification, none of these studies observed an OS benefit with auto-HCT consolidation. Based 
on these results, auto-HCT is not recommended as consolidation in first remission in FL. In 
relapsed/refractory FL, auto-HCT is largely used in fit patients, although perspective comparison 
studies with conventional salvage chemotherapy are rather weak. The National LymphoCare Study 
(NLCS) recently reported that patients with FL who experience relapse within 2 years of starting 
first-line immune-chemotherapy represent a biologically high-risk cohort with an extremely poor 
prognosis89. On the basis of these observations, the Center for International Blood and Marrow 
Transplant Research (CIBMTR) and NLCS recently investigated the role of auto-HCT in patients 
with FL who experience an early failure of immune-chemotherapy. A preliminary report of this 
analysis demonstrated that the early application of auto-HCT—that is, within 1 year of experiencing 
early failure—in patients with NLCS-defined high risk FL, was associated with an OS benefit 
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compared to similar patients who did not undergo auto-HCT. Contrary to auto-HCT, allo-HCT is 
potentially curative for patients with FL. The lower risk of relapse and durable remissions in 
patients with FL who underwent allo-HCT are due to graft-vs-lymphoma (GVL) effect. Registry 
data from the CIBMTR and the European Group for Blood and Marrow Transplantation (EBMT) 
demonstrate that a plateau in relapse risk occurs 2 to 3 years after allografting for FL, which 
indicates that a substantial proportion of these patients can be cured with allo-HCT90-91. Many 
prospective single-arm studies have evaluated the role of allo-HCT in relapsed/refractory FL 
employing reduced-intensity conditioning (RIC) regimen. RIC regimen provides disease control 
while facilitating donor cell engraftment, which allows the subsequent eradication of disease via the 
effects of GVL. RIC regimen is also safer in older and sicker patients. However, the majority of FL 
patients is >60 years at diagnosis and often present with comorbidities that can contraindicate allo-
HCT even with the RIC regimen. Choosing between auto and/or allo-HCT remains a controversial 
issue. The benefits of auto-HCT include relatively low morbidity and mortality. However, allo-HCT 
can be a reasonable alternative for patients who are candidates but have a contraindication for auto-
HCT, i.e: heavy marrow involvement or a difficulty to mobilize an adequate number of peripheral 
stem cells. CIBMTR conducted a registry study that compared auto-HCT with RIC allo-HCT in 
patients with FL who received R-based therapies before undergoing transplantation92. This analysis 
suggested that auto-HCT and allo-HCT, when applied as the first transplantation approach, provided 
comparable outcomes—PFS and OS—in relapsed/refractory FL. However, the risk of relapse was 
substantially lower after allo-HCT (even though the mortality was significantly higher). EBMT 
recently reported the outcomes of patients with FL who underwent RIC allo-HCT after auto-HCT 
failure93. The 5-year OS and PFS were 48% and 51%, respectively, and mortality was 27% at 2 
years, which suggests that RIC allo-HCT can be an effective salvage strategy in patients with FL 
who experience disease recurrence after prior auto-HCT. These results suggest that, in young and fit 
patients relapsing after several lines of immune-chemotherapy (and eventually auto-HCT), 
allogenic transplant is a powerful and potentially curable weapon. Nevertheless, for unfit/elderly 
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patients, other strategies should be considered with the aim of delaying progression and keeping the 
disease under control. With the advent of novel biological agents, the timing and the role of 
transplantation are dramatically changing: although disease eradication with the new drugs is not a 
reliable option at the moment, these can play a role in obtaining a better response both in clinical 
and molecular terms, deferring or even deterring the need for auto/allo-HCT. In addition, CAR-T 
cells, by eliciting a specific and durable immunologic response against tumor cells, could assume in 
the next future an alternative role to allo-HCT. 
 
2.6 Novel therapeutic approaches in FL 
The availability of agents targeting several other biological pathways is currently modifying the 
treatment algorithm for FL. Some of these have already been tested in first-line approaches, 
whereas the majority of data are available for relapsed/refractory FL. In this setting we are 
reviewing the most relevant ones. 
Lenalidomide is an oral immunomodulatory agent, derived from thalidomide, which has already 
shown activity toward Non Hodgkin Lymphomas (NHL) both a single agents as well as in 
combination. Fowler et al. have studied the role of lenalidomide and rituximab (R2) in untreated, 
advanced-stage NHL, including patients with FL (n=45), and reported an exciting ORR of 90%, 
with 87% CR (76% CR and 11% CRu) and 11% PR. The PFS at 3y was 78.5%94. Similar results 
have been obtained by Martin et al. in the ALLIANCE study, with an ORR of 95% (72% CR); at 2y 
and 5y PFS was respectively 86% and 70% and the 5y OS was 100%95. Nevertheless, a definitive 
answer about R2 effectiveness is awaited upon the results of the randomized RELEVANCE trial 
(Clinical Trails.gov - NCT01650701), which compares R2 vs the available standard chemotherapy 
(R-CHOP, BR, R-CVP). At the time of writing the results are not yet available, although they will 
be presented soon. The role of lenalidomide in maintenance is object of the MAGNIFY study 
(Clinical Trails.gov - NCT01996865), a phase 3b, multicenter, open-label study on patients with 
grade 1-3b or transformed FL. After an induction period, which includes 12 cycles of lenalidomide 
Ac
ce
pte
d M
an
us
cri
pt
plus R, patients are randomized to maintenance lenalidomide plus R or R alone. The primary 
endpoint is to evaluate the PFS and safety of this regimen. Within relapsed/refractory FL, Tuscano 
et al have shown that the R2 combination can produce durable clinical response: in 22 FL patients 
with a median of 3 prior lines of treatment treated with R2, the reported ORR was 77% (41% 
CR/CRu 41% and 36% PR)96. In another study (CALB 50401, Alliance) comparing lenalidomide 
alone vs R2, Leonard et al. showed that R2 was more active with an ORR respectively of 76.1% vs 
53.3%, CR 39.1% vs 20% and PR 37% vs 33.3%97. In the GALEN phase I trial, Morschhauser et al 
combined G and lenalidomide in patients with relapsed/refractory FL: in 20 patients, the ORR was 
68% with 54% CR.98. The recommended dose of lenalidomide and the efficacy of the combination 
of lenalidomide and G for relapsed FL is now object of another study (Clinical gov trial -  
NCT01582776). 
Ibrutinib is an oral inhibitor of Bruton’s tyrosine kinase which has already shown a certain grade 
of activity in relapsed/refractory FL. Advani et al. reported an ORR of 45.5% (27% CR) in 16 FL 
patients treated with ibrutinib99. Not very encouraging results also derived from the recent update of 
CONSORTIUM clinical trial: in 40 patients with relapsed FL, the treatment with ibrutinib single 
agent (560mg/day) resulted in an ORR of 37.5%, with 12.5% CR, a median PFS of 14 months and 
2-years PFS of 20.4%. Interestingly, the activity of Ibrutinib was higher in patients not refractory to 
R; by next generation sequencing approach, authors have identified CARD11 somatic mutation as a 
predictor of poor response to Ibrutinib100. In the future, this information may be useful to develop 
targeted therapies. More promising results are emerging from the combination of ibrutinib with 
other drugs: Fowler et al. combined ibrutinib with R in previously untreated FL patients (Clinical 
gov trial - NCT01980654). Patients received oral ibrutinib 560mg/die until progressive disease 
combined with 4 weekly doses of R (375 mg/m2). Preliminary data on 60 patients with a median 
follow-up of 10.2 months suggest an important clinical activity of the two agents with an ORR of 
82%, with a 27% CR and 55% PR. The use of chemo-free regimens does not mean toxicity-free: in 
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the same study the authors observed bleeding events in 32% of patients (only one Grade 2), atrial 
fibrillation in 5% and secondary malignancies in 7%. 
Idelalisib was the first phosphoinositide 3-kinase (PI3K) inhibitor approved by FDA (Food and 
Drug Administration) for the treatment of relapsed FL as monotherapy for patients who have 
received at least two prior systemic therapies101. In the phase II study that led to the registration of 
idelalisib for FL, Gopal et al. have shown antitumor activity in patients with indolent NHL who had 
received extensive prior treatments and became refractory to R and alkylating agents. In 72 patients 
with FL, after a median duration of treatment of 6.6 months, ORR was 57%, with 7% CR and 50% 
PR. The median duration of response (DOR) was 12.5 months with a PFS of 11 months. The most 
common adverse events were: serum elevation of hepatic aminotransfera e level in 47% patients, 
grade 3 transaminitis in 13%, grade 3 colitis or diarrhea in 13%102. A retrospective post hoc analysis 
demonstrated that idelalisib is also effective in high risk patients with FL: 37 patients with early 
progressive disease (PD) treated with idelalisib showed an ORR of 56.8% (13.5% CR and 43.2% 
PR). The DOR was 11.8 months101. Based on these results, within high risk refractory patients, 
idelalisib may represent a valid opportunity though other propsective studies are necessary.  
Nevertheless, caution should be advised for the occurrence of unexpected toxicity: an excessive 
mortality was observed compared to placebo103. Thus, an adequate Pneumocystis prophylaxis and 
Cytomegalovirus monitoring are recommended. A phase-I clinical trial investigated the 
combination of idelalisib and R2 in relapsed/refractory FL and mantle cell lymphoma (MCL). 
Unfortunately, this combination showed excessive toxicities including grade 3 or higher 
transaminitis, hypotension, rash, sepsis syndrome, and pulmonary infiltrates, leading to interruption 
of the study103. The results of phase-III BRIDALVEIL trial investigating the combination of 
Idelalisib plus BR are awaited (Clinical gov trial - NCT01732926). 
Copanlisib
104 is an intravenous pan-class PI3K inhibitor with predominant and potent activity 
against the PI3K-α and PI3K-δ isoforms, recently approved by FDA for the treatment of patients 
with relapsed FL who have received at least two prior systemic therapies. A phase II study has 
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demonstrated the activity of Copanlisib: in 104 FL patients the ORR was 59% with 12% CR, DOR 
was 22.6 months and PFS 11.2 months105. 
Other PI3K inhibitors (i.e. Duvelisib and others) are also currently being investigated for the 
treatment of relapsed FL, with promising results106.  
The emerging role of check point inhibitors in the treatment of B-cell Lymphomas is now object 
of study. Nivolumab is a fully human IgG4 PD-1 (Programmed Death-1) immune checkpoint 
inhibitor antibody that binds PD-1 receptors on T cells and disrupts negative signaling triggered by 
PD-L1/PD-L2 to restore T-cell antitumor function.107. The efficacy of Nivolumab is related to PD-1 
levels of intratumoral T cells; in FL, PD-1 is highly expressed108 and preliminary results of phase-Ib 
study seem to demonstrate some activity of Nivolumab in previously treated patients with FL. In 
this study the ORR was 40% in FL (10 patients), with 10% CR, 30% PR and 60% SD with 
manageable toxicity109. Other studies are necessary to confirm these data and to evaluate the 
duration of response. The use of checkpoint inhibitors seems to be more promising in combination 
with other agents: an open-label, non-randomized, single institution, phase II trial has tested 
pembrolizumab combined with R for the treatment of R/R NHL. The ORR was 80% with 60% CR, 
and a reported acceptable toxicity profile110.  
Despite the constitutive BCL2 expression represents one of the hallmark pathogenic pathways in 
FL, BCL2 inhibitors did not show equivalent efficacy as observed in CLL and other hematologic 
malignancies. Venetoclax is an oral highly selective BCL2 inhibitor which was reported to restore 
the apoptotic ability of malignant cells111. A phase I study, investigating the effect of Venetoclax 
monotherapy in 29 patients with R/R FL, reported an ORR of 38%, with 14% CR and 24% PR112. 
Chimeric Antigen Receptor (CAR) T cells are emerging as a novel treatment for patients with 
NHL resistant to standard therapies, as well as other lymphoproliferative diseases. Different clinical 
trials have demonstrated an important activity of anti-CD19 CAR T-cells against some types of 
NHL including refractory FL. A recent trial by Schuster et al. investigated the activity of autologous 
T cells expressing CD19-directed CAR (CTL019) in patients with relapsed or refractory DLBCL 
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and FL113. A total of 28 patients (14 with FL) received CTL019 cells and the ORR was 64%, with 
71% CR in patients with FL. Notably, with a median follow-up of 28.6 months, 89% of patients had 
maintained the response. CAR-T cells however are associated with potential toxic effects including 
cytokine release syndrome (CRS) that in this trial occurred in 5 patients (18%) and encephalopathy 
that occurred in 3 patients with 1 fatal case. CAR T cells seem to be a promising therapeutic 
approach for NHL, especially for patients who are refractory to multiple lines of chemotherapy, 
exhibiting a remarkable ability in obtaining durable CR. On the other hand, it is necessary to 
improve the security profile. In terms of management, IL6 is thought to be the main driver of CRS 
and for that reason the IL6-R antagonist, tocilizumab has been FDA-approved to mitigate this 
toxicity. 
Biosimilar drugs: Despite the introduction of new MoAbs as potential substitutes to R, it is widely 
accepted that R remains the standard anti-CD20 moAb for the treatment of FL because of its 
established long-term efficacy. However, composition-of-matter patent of R is currently expired 
and this has opened the way to new cost-effective compounds. Moreover, many countries with 
restricted resources still do not have access to patented R. For these reasons, new biosimilar drugs 
have been introduced114. “Biosimilar” refers to a biologic product that is highly similar to an 
approved product, except for minor differences in clinically inactive components, and for which 
there are no clinically meaningful differences in potency, purity, or safety. Some of the newly 
developed biosimilars for FL are: CT-P10 (Celltrion), GP2013 (Sandoz), PF-05280586 (Pfizer) and 
ABP 798 (Amgen). A randomized non-inferiority phase III trial investigated the use of CT-P10 
compared with R in patients with untreated advanced stage FL. This study successfully confirmed 
the non-inferior efficacy, pharmacokinetics and safety of CT-P10115. Another biosimilar 
(Truxima™) has recently been granted approval for the treatment of NHL and CLL. A clinical 
study in patients with previously untreated FL showed therapeutic equivalence in ORR and similar 
efficacy, pharmacokinetic, and pharmacodynamic between GP-2013 and R116. Other biosimilars in 
development for FL are: ABP 798 (for CD20-positive B-cell NHL; ClinicalTrials.gov - 
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NCT02747043), BI-695500 (for LTBFL; ClinicalTrials.gov -  NCT01950273), and PF-05280586 
(for LTBFL; ClinicalTrials.gov - NCT02213263). The final development of one or more R-
biosimilars will be crucial to solve the lack of access to R in some countries and generate cost 
savings for health care systems worldwide. 
 
3. Expert Commentary and 5-year view 
In localized stage FL, the current recommendation is a local irradiation of the involved lymph 
node(s), although it is not always attended by the physicians. Nevertheless, this approach achieves 
eradication of the disease only in about half of patients. An accurate identification of patients at 
high risk of relapsing, could address to a specific consolidation. Stringent evaluation of MRD with 
novel biomolecular techniques could be useful to lead an appropriate treatment in this subset of 
patients.  
Patients with asymptomatic, advanced stage, LTBFL, that are currently managed with a watch and 
wait approach, represent an heterogeneous group: some of them will not require therapy for 10 
years after diagnosis, while many other necessitate the initiation of an early treatment. More 
accurate prognostic scoring systems could help to identify a more appropriate and personalized 
approach. 
Several weakness points are still evident also in management of treatment-requiring patients 
affected by FL. The available prognostic systems do not fully allow to identify high risk patients at 
diagnosis. The methods which incorporate molecular biology such as m7-FLIPI or gene expression 
profiling have improved the stratification, however the best indicator is POD24, available only after 
the induction treatment, 2 years from diagnosis. Thus, at present, the best applicable strategy is to 
modify the therapeutic approach on the base of the evaluation of the response to induction, using 
highly predictive methods such as: PET TMTV, MRD. The Italian FOLL12 ongoing trial will 
evaluate the efficacy of a personalized post-induction strategy based on these methods, compared to 
the standard of care. 
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The second weakness point in the management of the disease is that currently adopted therapeutic 
strategies have been based on several subsequent studies aimed at prolonging the response to 
therapy of a virtually incurable disease. Although this approach is surely agreeable in elderly ones, 
in young and fit patients it is probably time to persecute the goal of disease eradication. Indeed, in 
the experience of physicians managing FL, a minority of patients never relapse following modern 
treatment strategies. Hence, a change of strategy in this direction is nowadays to be considered. The 
quality of response evaluation employing sophisticated biomolecular techniques and PET could 
help in directing specific treatment strategies. As for more aggressive lymphomas, in which the 
mutation status of specific genes has been cleared to be useful for specific treatment strategies, this 
may become true also for indolent lymphomas in the next future. It is possible that new biologic 
agent combinations, the adoption of strategies aimed at augmenting the immune response against 
the disease or CAR-T cells could eventually lead to this goal.  
 
 
Key issues  
 
• The current prognostic options for FL are being innovated to better define groups of patients 
with different outcomes. The integration of molecular diagnostics (MRD, NGS mutational 
status and gene-expression panels) as well as PET, will help to identify patients who could 
benefit of different personalized therapeutic approaches. 
• The use of conventional immune-chemotherapeutic regimens is still the gold-standard 
approach for FL patients. The definition of treatment initiation in early stages (I-II) and 
advanced stage (III-IV) low-tumor burden FL is still matter of discussion. The debate is 
between giving a treatment capable of prolonging the indolent state of the disease with low 
profiles of toxicities or maintain a “watch & wait” approach. 
• The use of auto/allo stem cell transplantation is currently being delayed and, in some cases 
potentially avoided, thanks to the introduction of novel therapies.  
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• New agents are showing activity in patients with relapsed/refractory FL. These include 
MoAbs, kinase and check-point inhibitors and adoptive cell transfer therapies. However, a 
long-term follow-up will establish whether these agents will have an impact on OS and 
confirm their role in the clinical practice. 
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Table 1. Role of post-induction PET in follicular lymphoma. 
 LYSA trial PRIMA36 FIL FOLL0537 GOELAM trial38 
Patients (n) 122 202 121 
Treatment 
R-CHOP vs R-CVP 
+/- R- maintenance 
R-CHOP vs R-CVP vs 
R-FM R-CHOP 
PET+ after induction 
therapy 
26% 24% 22% 
PFS PET+ vs PET- 
32,9% vs 70,7% 
at 42 months 
(HR 3,3; p<0.001) 
35% vs 66% 
at 36 months 
(HR 2,59; p<0.001) 
51% vs 87% 
at 23 months 
(HR 6,6 ; p<0.0001) 
OS PET+ vs PET- 
78,5% vs 96,5% 
at 42 months 
(p=0.001) 
_ 
88% vs 100% 
at 24 months 
(p=0.0128) 
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Table 2. Trials reporting the results of IF-RT alone for stage I-II follicular lymphoma.  
Authors 
Pts 
(n) 
Total RT 
dose (Gy) 
RT Volume 
Follow-
up (yrs)
PFS 
(%) 
OS (%) 
Paryani et al, 198353 26 35-50 IF, EF, TNI 5,5 
5-yr: 62  
10-yr: 
54     
15-yr:  
42 
5-yr: 84  
10-yr: 68  
15-yr:    
40 
Gospodarowicz et al, 
198454 248 
20-50      
(86%: <35) IF 12 
5-yr: 56  
10-yr: 
53 
5-yr 73  
10-yr     
58 
Vaughan Hudson et al, 
199655 208 35 NS 10 
10-yr: 
47 
10-yr 
CSS: 71-
84 
MacManus et al, 199656 177 35-44 IF, EF, TNI 7,7 
5-yr: 55  
10-yr: 
44      
15-yr: 
40 
5-yr: 82  
10-yr: 64  
15-yr:    
44 
Stuschke et al, 199757 117 26 + 10 EF, TNI 5,7 
5-yr: 71  
10-yr: 
59 
5-yr: 86  
10-yr:    
86 
Neumann et al, 200358 116 20-50 IF, EF, TNI 4 
5-yr: 62  
10-yr: 
48 
5-yr: 76  
10-yr:    
51 
Petersen et al, 200459 460 16-47.5 IF 12,5 
5-yr: 56  
10-yr: 
41 
5-yr: 79  
10-yr:    
62 
 
Abbreviations: IF (involved field); EF (extended field); TNI (total nodal irradiation); NS (not 
specified); CSS (cancer specific survival). Adapted by Filippi AR et al14  
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Table 3. Trials reporting R as single agent or in addition to standard IF-RT for stage I-II 
follicular lymphoma.  
Authors Pts (n) Treatment R Dose  
Follow-
up (yrs) 
PFS  
Janikova et al, 201545 93 IF-RT vs IF-RT + R vs R alone 
375 mg/m2 
weekly   x 4-8 
doses 
3.4 
IF-RT: 3.3 yrs 
(median)                     
R: 4,9 yrs (median)     
IF-RT+R: not 
reached 
Cencini et al, 201750 41 IF-RT vs IF-RT + R 
375 mg/m2 
weekly   x 4 
doses 
3.8 5-yr: 90 %        
Mondello et al, 
201446 108 
IF-RT vs IF-RT + R 
vs R alone 
375 mg/m2 
weekly   x 4-8 
doses 
1 
IF-RT: 2.3 yrs 
(median)                     
R: 5 yrs (median)        
IF-RT+R: 6 yrs 
(median) 
Ruella et al, 201651 94 IF-RT vs IF-RT + R 
375 mg/m2 
weekly   x 4 
doses 
10.9 
10-yr (IF-RT): 
50.7%                10-
yr (IF-RT+R): 64.6%
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Table 4. GELF criteria for high tumor burden disease definition (adapted from (15) with 
permission) 
High tumor burden defined by at least one of the following: 
- Involvement of three distinct nodal sites, each with a diameter of 3 cm 
- Any nodal or extranodal (except spleen) tumor mass with a diameter of 7 cm 
- Symptomatic splenomegaly (enlarged spleen) 
- Cytopenias (leukocytes < 1.0 x 10/l and/or platelets <100 x 10/l 
- Leukemia (>5.0 x 10/l malignant cells) 
- Pleural effusions or peritoneal ascites 
B symptoms 
Elevated LDH or beta2-microglobulin (>3g/dl) 
ECOG PS (>1) 
 
 
 
 
